Strategy for genotoxicity testing: Hazard identification and risk assessment in relation to in vitro testing
V. Thybaud(Sanofi (France)), Errol Zeiger, Wakako Ohyama(Yakult Central Institute), Marilyn J. Aardema(Procter & Gamble (United States)), Makoto Hayashi(Nagasaki University Hospital), David Jacobson‐Kram(United States Food and Drug Administration), Sheila M. Galloway(United States Military Academy), David Kirkland(Covance (United States)), Hiroshi Suzuki(University of Tokyo Hospital), Daniel Marzin(Université de Lille), James T. MacGregor, Maik Schuler(Pfizer (United States)), Kerry L. Dearfield(Food Safety and Inspection Service), Julie Clements(Covance (United Kingdom))
Mutation Research/Genetic Toxicology and Environmental Mutagenesis
November 28, 2006
Cited by 131
Related Papers
Chromosome aberrations and sister chromatid exchanges in chinese hamster ovary cells: Evaluations of 108 chemicals
|Environmental and Molecular Mutagenesis|1987|661
A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity
|Regulatory Toxicology and Pharmacology|2006|461
How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2007|437
Common Defects of ABCG2, a High-Capacity Urate Exporter, Cause Gout: A Function-Based Genetic Analysis in a Japanese Population
|Science Translational Medicine|2009|434